Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stinchcombe

Showing results (461-470 of 575) with videos related to

Pageof 58
Sort By:
International Journal of Radiation Oncology, Biology, Physics|April 12, 2011
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105Joseph K Salama, Thomas E Stinchcombe, Lin Gu, et al.
Journal of Geriatric Oncology|February 25, 2019
Clinical prognostic model for older patients with advanced non-small cell lung cancerApar Kishor Ganti, Xiaofei Wang, Thomas E Stinchcombe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2020
Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global PandemicSameera Kumar, Steven Chmura, Clifford Robinson, et al.
International Journal of Cancer|October 17, 2019
Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survivalSen Yang, Dongfang Tang, Yu C Zhao, et al.
The New Phytologist|October 14, 2025
Unraveling complexity in climate change effects on beneficial plant-microbe interactions: mechanisms, resilience, and future directionsMichelle E Afkhami, Aimée T Classen, Collin G Dice, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancerThomas E Stinchcombe, David E Morris, Carrie B Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2008
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancerThomas E Stinchcombe, Harry D Harper, Thomas A Hensing, et al.
Cancer Immunology, Immunotherapy : CII|March 2, 2021
Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survivalSen Yang, Dongfang Tang, Yu Chen Zhao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancerRebecca S Heist, Xiaofei Wang, Lydia Hodgson, et al.
Cancer|October 23, 2025
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancerHirva Mamdani, Ryan D Gentzler, Lin Gu, et al.
Pageof 58

Showing results (461-470 of 575) with videos related to

Sort By:
Pageof 58
International Journal of Radiation Oncology, Biology, Physics|April 12, 2011
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105Joseph K Salama, Thomas E Stinchcombe, Lin Gu, et al.
Journal of Geriatric Oncology|February 25, 2019
Clinical prognostic model for older patients with advanced non-small cell lung cancerApar Kishor Ganti, Xiaofei Wang, Thomas E Stinchcombe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2020
Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global PandemicSameera Kumar, Steven Chmura, Clifford Robinson, et al.
International Journal of Cancer|October 17, 2019
Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survivalSen Yang, Dongfang Tang, Yu C Zhao, et al.
The New Phytologist|October 14, 2025
Unraveling complexity in climate change effects on beneficial plant-microbe interactions: mechanisms, resilience, and future directionsMichelle E Afkhami, Aimée T Classen, Collin G Dice, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancerThomas E Stinchcombe, David E Morris, Carrie B Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2008
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancerThomas E Stinchcombe, Harry D Harper, Thomas A Hensing, et al.
Cancer Immunology, Immunotherapy : CII|March 2, 2021
Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survivalSen Yang, Dongfang Tang, Yu Chen Zhao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancerRebecca S Heist, Xiaofei Wang, Lydia Hodgson, et al.
Cancer|October 23, 2025
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancerHirva Mamdani, Ryan D Gentzler, Lin Gu, et al.
Pageof 58